International Board of Directors

Meet the 2019–2020 ISPE International Board of Directors


ISPE is pleased to announce the results of our 2019–2020 International Board of Directors election. The Board is responsible for the governance and strategic direction of the Society and will assume their elected positions at the 2019 ISPE Annual Meeting & Expo, 27–30 October in Las Vegas, Nevada USA.

The following pharmaceutical industry leaders have been elected to positions on the 2019–2020 ISPE International Board of Directors:

Officers

Frances M. Zipp
President & CEO
Lachman Consultant Services, Inc
Chair
Contact
Term: 2019 – 2020
Thomas B. Hartman
VP, GMP Operations
GlaxoSmithKline
Vice Chair
Contact
Term: 2019 – 2020
Joanne R. Barrick, RPh
Advisor, Global Validation
Eli Lilly and Company
Treasurer 
Contact
Term: 2019 – 2020
Jörg Zimmermann
Vice President/Bereichsleiter
Vetter Pharma-Fertigung GmbH & Co.
Secretary
Contact
Term: 2019 – 2020
James A. Breen, Jr., PE
Vice President, Lead Biologics Expansion
Janssen Pharmaceuticals
Past Chair
Contact
Term: 2019 – 2020
John Bournas
CEO and President
ISPE
Ex officio non-voting member
Contact

Directors

Vivianne J. Arencibia
Independent Consultant
Arencibia Quality Compliance Associates
Contact
Term: 2018 – 2020 (Second term)
Gunter Baumgartner
Senior Vice President, Head of Global Engineering
Takeda Pharmaceuticals International AG
Contact
Term: 2018 – 2020 (Second term)
Scott W. Billman
Sr. Director Global Engineering
Biogen
Contact
Term: 2019 – 2020 (First term)
Chris Chen, PhD
CEO
WuXi Biologics (Shanghai) Co., Ltd.
Contact
Term: 2018 – 2020 (Appointed)
Ylva Ek
Chief Quality Officer (CQO)
KeyPlants AB
Contact
Term: 2019 – 2020 (First term)
Lou W. Kennedy
CEO and Owner
Nephron Pharmaceuticals
Contact
Term: 2019 – 2020 (First term)
Stephen C. Mahoney, JD
Senior Director, Global Quality & Compliance
Genentech
Contact
Term: 2019 – 2020 (First term)
Christine M. V. Moore, PhD
Global Head and Executive Director, GRACS CMC Policy
Merck & Co.
Contact
Term: 2018 – 2020 (Second term)
Alice Redmond, PhD
Vice President, European Operations
Commissioning Agents International (CAI)
Contact
Term: 2017 – 2020 (Third term)
Caroline Rocks, CEng
Senior Program Manager
AbbVie, Inc.
Contact
Term: 2018 – 2020 (Second term)

Ex Officio

LeAnna M. Marcum
Manager QA Validation
BlueBird Bio
Board Young Professionals Representative (Non-voting)
Contact
Term: 2018 – 2020 (Second term)

2018-2019 Board

The ISPE International Board of Directors 2018 Election has concluded and the results are in. Below is the list of those Members who have been elected to serve on the 2018-2019 Board of Directors.

The leadership transition between the 2017-2018 Board and the 2018-2019 Board will take place during the ISPE Annual Meeting & Expo in November in Philadelphia, PA.

Officers

James A. Breen, Jr., PE
Vice President, Lead Biologics Expansion
Janssen Pharmaceuticals
Chair
Contact
Term: 2018 – 2019
Frances M. Zipp
President & CEO
Lachman Consultant Services, Inc
Vice Chair
Contact
Term: 2018 – 2019
Thomas B. Hartman
VP, GMP Operations
GlaxoSmithKline
Treasurer
Contact
Term: 2018 – 2019
Joanne R. Barrick, RPh
Advisor, Global Validation
Eli Lilly and Company
Secretary
Contact
Term: 2018 – 2019
Past Chair
Contact
Term: 2018 – 2019
John Bournas
CEO and President
ISPE
Ex officio non-voting member
Contact
Term: 2019 – 2020

Directors

Vivianne J. Arencibia
Independent Consultant
Arencibia Quality Compliance Associates
Contact
Term: 2018 – 2020 (First term)
Gunter Baumgartner
Senior Vice President, Head of Global Engineering
Takeda Pharmaceuticals International AG
Contact
Term: 2018 – 2020 (First term)
Chris Chen, PhD
CEO
WuXi Biologics (Shanghai) Co., Ltd.
Contact
Term: 2018 – 2020 (Appointed)
Antonio C. Crincoli, PE
Senior Director, Head Upjohn Global Engineering
Pfizer Inc.
Contact
Term: 2017 – 2019 (Second term)
Flemming Dahl
Head of Quality, Senior Vice President
Novo Nordisk A/S
Contact
Term: 2017 – 2019 (First term)
Kelly M. Keen
Vice President, Head of PMO Project Management
Celonic Ag
Contact
Term: 2017 – 2019 (First term)
Christine M. V. Moore, PhD
Global Head and Executive Director, GRACS CMC Policy
Merck & Co.
Contact
Term: 2018 – 2020 (Second term)
Alice Redmond, PhD
Vice President, European Operations
Commissioning Agents International (CAI)
Contact
Term: 2017 – 2019 (First term)
Caroline Rocks, CEng
Senior Program Manager
AbbVie, Inc.
Contact
Term: 2018 – 2020 (First term)
Michael L. Rutherford
Executive Director, Computer Systems Quality and Data Integrity
Syneos Health
Contact
Term: 2017 – 2019 (Second term)

Ex Officio

LeAnna M. Marcum
Manager QA Validation
BlueBird Bio
Board Young Professionals Representative (Non-voting)
Contact
Term: 2018 – 2019

ISPE is governed by an elected board of directors. The board is composed of fifteen elected members and the CEO & President, who serves as a non-voting ex-officio member. Directors are elected to a two-year term and can serve up to two terms consecutively. All terms commence at Annual Meeting. The officer positions are Chair, Vice Chair, Treasurer, Secretary, Past Chair and the President as a non-voting ex officio member. Terms for officers are one year and the Secretary is the first officer position in the typical officer succession. Each candidate for secretary is typically making a five-year commitment to serve in the roles of Secretary through Past Chair. During the September 2016 meeting of the ISPE International Board of Directors, two important modifications were incorporated into the ISPE Bylaws. The Board approved the appointment of a Director level position to the Board and the current Chair of the International Young Professionals Committee will be invited to board meetings as an ex-officio (non-voting) member as well. The main objective of these appointments was to ensure that ISPE has the appropriate diversity within the Board to execute business strategies as defined in our ISPE Strategic Plan. For additional information on the actions from the last Board meeting or access to governance actions visit the Governance Documents FAQs page.